Objective. Case reports of sudden sensorineural hearing loss (SSHL) following vaccines have led to concerns that vaccines may rarely cause hearing loss. Because of this concern, we analyzed for an association between SSHL and vaccinations.
Background
Sudden sensorineural hearing loss (SSHL) is generally idiopathic but in some cases may be associated with infections, vasculitides, tumors, certain genetic conditions, and cardiovascular risk factors. 1, 2 Anecdotal case reports of SSHL following vaccines have speculated that vaccines might be the cause of hearing loss in some cases. [3] [4] [5] [6] [7] Case Report A healthy man in his 30s presented with sudden onset of right-sided tinnitus and hearing loss 6 days after receiving a trivalent inactivated influenza vaccine (TIV). The patient reported slight, intermittent dizziness but denied fever, congestion, or headache, and he had no known risk factors for hearing loss. His head and neck examination was normal. The patient had taken an appropriate dosage of ibuprofen for 2 days after TIV for self-limited, non-ear-related pain but stopped 2 days before the onset of hearing loss. His primary care provider advised decongestants, but these provided no relief of symptoms. The patient was referred to otolaryngology for further evaluation. Audiogram revealed normal hearing in the right ear to 2000 Hz, then a precipitous drop to profound hearing loss in the higher frequencies.
Pure tones in the left ear were normal. Word recognition scores were 100% in both ears, and tympanograms were type A. Audiology testing performed 6 years earlier was normal bilaterally. Magnetic resonance imaging (MRI) of the brain with and without gadolinium, focused on the internal auditory canal, was normal. He was diagnosed with SSHL and treated with a prednisone taper. At the time this case occurred, intratympanic steroids were not commonly used; oral steroids alone were the standard of care. His hearing did not improve. Because of the temporal association between the SSHL and immunization, the patient's otolaryngologist brought the case to the attention of Centers for Disease Control and Prevention's (CDC's) Clinical Immunization Safety Assessment (CISA) Project to assess whether there might be a causal association between receipt of TIV and onset of SSHL. The CISA Project is a national network of vaccine safety experts from the CDC's Immunization Safety Office (ISO), 7 medical research centers, and other partners that conducts vaccine safety research and provides comprehensive clinical consultations for US health care providers regarding complex or unusual vaccine adverse events in their patients (http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/ cisa/index.html). In 2014, CISA contracted with Kaiser Permanente Northern California (KPNC) to pilot application of case-centered analytic methods to assess whether specific vaccine adverse events might be associated with an increased likelihood of receipt of one of more vaccines during a risk interval. A risk interval is the biologically plausible time period during which an adverse event following an immunization might occur. 8 Results of these analyses have supplemented other information reviewed during CISA clinical case consultations, including medical records, scientific literature, manufacturer package inserts, similar adverse event reports from the Vaccine Adverse Event Reporting System (VAERS), 9 and expert opinion.
To assess for an epidemiological association between immunizations and SSHL, we performed a case-centered analysis within KPNC. Here we report the findings of this analysis.
Methods
Our analysis used a case-centered risk interval design, as has been used in multiple vaccine studies. [10] [11] [12] [13] [14] [15] [16] [17] Case-centered analyses look back from the date of onset of the case to determine whether vaccinations cluster in the risk interval prior to the onset. In this method, the observed odds of exposure (immunization) during the risk interval prior to the outcome are compared with the expected odds of exposure during the same risk interval, based on vaccination times in the population of all similar persons vaccinated with the same vaccine of interest. The method is equivalent to a matched case-control study, which uses all matched controls (no sampling) and is anchored to an index date for each case. Each case of SSHL, from the electronic search, was matched by age and sex to all KPNC members who, as of the onset date of the case SSHL, received the same vaccine as the case in the 9 months prior to the onset date of the index case. The onset date was set to the first hearing-related diagnosis in the 2 months prior to the SSHL diagnosis, as noted in Cases below. All cases and matched comparison KPNC members were vaccinated in the 9-month period prior to the onset of SSHL in the cases, and we determined the proportion of cases vaccinated within predetermined risk intervals compared with the rest of the 9 months prior to vaccination (29 days through 9 months), as well as the proportion of matched controls vaccinated in the same risk interval time period, with the same vaccine, using Cox regression. Stratified exact methods were used, with a mid-P adjustment for the 2-sided tests and test-based confidence intervals, as previously described. 18 
Study Population
This study used electronic medical records from KPNC, which provides integrated medical services to over 3.5 million members. For this study, we used data including all the years from 2007 through 2013 and required 1 year of membership prior to the diagnosis.
Cases
We searched internal KPNC databases for all first-ever (within all available data) diagnoses of SSHL, using internal electronic medical record text codes, which are more detailed and specific than International Classification of Diseases, Ninth Revision (ICD-9) codes. As illustrated in the presenting case, a diagnosis of SSHL is often delayed until the patient is seen by an otolaryngologist. For this reason, to better identify the date of symptom onset, we first searched for all diagnoses during the 60 days prior to the diagnosis of SSHL and chose from among those the diagnoses that could possibly have been related or been a precursor to an SSHL diagnosis. These diagnoses included deafness, hearing loss, tinnitus, ear pain, otitis, and dizziness. We used the first date for these diagnoses as the index date for the case.
We randomly selected 25 SSHL cases from the electronic medical records that were seen within 2 weeks of immunization and 25 cases that were vaccinated outside the 2-week period but within 9 months prior to onset, for medical records review, to determine whether the case was new (not a ''history of'') and whether the clinician truly made the diagnosis.
Exposure
We examined all vaccines for which over 20,000 doses were given at KPNC in the 7-year study period.
Risk and Comparison Intervals
To guide our selection of the appropriate risk intervals, we reviewed the literature, obtained expert opinion, and used database searches. We searched the Vaccine Adverse Event Reporting System (VAERS) downloadable data (https:// vaers.hhs.gov/data/data) among reports received from June 1, 1990, through February 4, 2015, for hearing-related diagnoses in patients who received TIV alone (no concomitant vaccines). Among the 13 reports of adults diagnosed with sensorineural hearing loss, the median onset from receipt of TIV to onset of tinnitus and/or hearing loss was 2 days (mean, 3 days; range, 0-12 days). On the basis of this search and our other criteria, we selected risk intervals of 1 to 7 and 1 to 14 days for our primary analyses. To address concerns that SSHL onset might be delayed in some cases beyond the 1-to 14-day primary risk interval, we performed secondary analyses using risk intervals of days 1 to 28 and days 15 to 28 prior to onset. As a comparison interval, we used all observation time outside the 28-day risk interval in the 9 months prior to immunization (day 29 through 9 months). Nine months was selected to minimize flu vaccine receipt over successive seasons.
Given the number of vaccines administered and the incidence of SSHL, we had 80% power to detect, in the 1-to 7day risk interval, a relative risk of 1.88 for TIV, 2.57 for tetanus reduced diphtheria acellular pertussis (Tdap), 4.3 for pneumococcal polysaccharide (Pneumovax), and 1.52 for any vaccine.
This study was approved by the KPNC Institutional Review Board.
Results
In the KPNC databases, we detected a total of 1929 cases of SSHL within 9 months of any vaccine. Of these, 57 (3.0%) were within 1 week of a vaccine. All 50 randomly selected SSHL cases were verified by chart review as new incident cases.
During the course of the study, over 20 million vaccines were given. The frequency and distribution of the vaccines are shown in Table 1 .
Influenza Vaccines
We found no increased risk of prior TIV vaccination in patients with SSHL in any of the prespecified risk intervals ( Table 2 ). The odds ratio point estimates ranged from 0.87 to 1.235, all upper 95% confidence bounds were less than 1.7, and none of the risk intervals for TIV were statistically significantly elevated.
Other Vaccines
Among the noninfluenza vaccines, there were no vaccines with a statistically significant elevated odds ratio of prior immunization in any risk interval compared with the rest of the prior 9 months ( Table 3) . Although the quadrivalent human papillomavirus (HPV4) vaccine had an odds ratio point estimate of 4.155, this finding was based on only 1 Only vaccines with more than 20,000 doses were studied.
case in the risk interval and had wide confidence intervals (CIs). Analyses evaluating all noninfluenza vaccines during the different risk intervals (1-14 days, 1-28 days, and 15-28 days) demonstrated similar results in that there were no statistically significant increases in the odds of vaccination in any of the risk intervals prior to the onset of SSHL (see Supplemental Material at www.otojournal.org/supplemental).
Discussion
The etiology of most cases of SSHL is unknown. 2 Cardiovascular risk factors may play a role, as may hypercoagulable states, 1 tumors, autoimmune diseases, 19 and diet. 20 Viral and bacterial infectious diseases 2 have also been postulated as causes of SSHL, and this has led to speculation that vaccines may also potentially play a role.
Review of the 13 VAERS reports of SSHL following TIV seemed to indicate the possibility of clustering in time of SSHL with respect to TIV vaccination; however, temporal association does not prove causation when assessing the association of vaccine adverse events. Our application of case-based statistical methods clearly demonstrated no clustering of either TIV or any other vaccine prior to the outcome of SSHL. The control interval is the 9 months prior to immunization, excluding the 28-day risk interval. The control interval is the 9 months prior to immunization, excluding the 28-day risk interval.
This study was reassuring with regard to all vaccines studied. With 7 years of follow-up, monitoring over 23 million vaccines, we found no indication of an increased risk of immunization with any vaccine prior to the development of SSHL. Reassurance of vaccine safety is critical to maintain high levels of immunization and protect the public's health, particularly in these times of increasing vaccine hesitancy.
By using only cases and controls that are vaccinated with the same vaccine at some time in the past 9 months, the case-centered method controls very well for inherent differences between vaccinated and unvaccinated persons. Casecentered methods are anchored to the calendar date of the outcome onset (ie, controls are matched to cases based on calendar date) and, hence, control extremely well for timevarying confounding, such as seasonality. The method also controls very well for age, with cases matched very finely to controls by age and vaccine.
Members of KPNC are similar in race and socioeconomic status to the rest of the state of California, although as an insured population, they underrepresent the very poor. 21 The health plan covers all routine medical care, and patients receive essentially all care within KPNC facilities. Vaccines are provided at no additional cost and are easy to obtain, so most vaccines, including influenza, are administered within the health plan. Diagnoses from hospital stays, outpatient and emergency department visits, medications, laboratory tests, immunizations, imaging, and other ancillary tests are all linked via a unique medical record number that stays with each member throughout his or her life.
Our study has some limitations. Cases were not all individually reviewed to confirm the diagnosis, so there could be some misclassification of diagnosis or onset date; however, our review of 50 random cases verified that the electronic diagnosis was highly specific. Power was dependent on the number of vaccines given. For vaccines such as TIV, with over 8 million doses, we are able to provide strong evidence against an association with SSHL, whereas with some vaccines, such as yellow fever, our confidence intervals are wide. In addition, since SSHL is often transient or mild, many affected persons may not present for care. Our study only speaks to those with medically attended SSHL. In addition, the risk intervals were selected through literature and VAERS review as well as consultation with experts. If the interval selected does not match the timing of increased risk, an association may be missed.
Conclusions
Many people, physicians and patients alike, make the presumption that if an event follows immunization, it is due to immunization. This study illustrates the fallacy in that thinking and reminds us that, since we are often giving vaccines, some adverse events are bound to happen shortly after immunization, due to random chance alone. However, when we consider millions of people and millions of vaccines, we see that SSHL was not significantly increased after immunization; hence, sporadic cases are very unlikely to be caused by vaccines. Through this study, we are appreciating how the application of case-based statistical methods can be an effective tool for helping to guide expert clinical and epidemiological assessment of vaccine adverse event causality.
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